Abstract
The immunogenicity and safety of Pfizer-BioNTech BNT162b2 mRNA vaccine in allogeneic haematopoietic stem cell transplantation (HSCT) recipients are unknown. We prospectively followed 152 HSCT recipients who were at least six months following transplantation and with no active acute graft-versus-host disease (GVHD). Blood samples were taken 2-4 weeks after the second vaccination and analyzed for receptor-binding domain (RBD) antibodies and neutralizing antibodies (NA). 272 immunocompetent healthcare workers served as controls. At a median of 28 days after the second vaccination, 118 patients (77·6%) developed RBD immunoglobulin G (IgG) with a geometric mean titre (GMT) of 2·61 [95% CI (confidence interval), 2·16-3·16]. In the control group 269/272 (98·9%) developed RBD IgG, with a GMT of 5·98 (95% CI 5·70-6·28), P < 0·0001. The GMT of NA in HSCT recipients and controls was 116·0 (95% CI 76·5-175·9), and 427·9 (95% CI 354·3-516·7) respectively (P < 0001). Multivariate logistic regression analysis revealed that HSCT recipients with no chronic GVHD and no immunosuppressive therapy at the time of vaccination had significantly higher levels of NA following the second vaccination. Adverse events were minimal and were less common than in healthy controls. In conclusion; the BNT162b2 mRNA vaccination is safe and effective in HSCT recipients, especially those who are immunosuppression-free. A significant fraction developed protecting NA.
Keywords: COVID-19; haematopoietic stem cell transplantation; neutralizing antibodies; vaccination.
【저자키워드】 COVID-19, vaccination, Neutralizing antibodies, haematopoietic stem cell transplantation, 【초록키워드】 neutralizing antibody, IgG, vaccination, therapy, antibody, healthcare worker, Immunoglobulin, RBD, Patient, Control, Allogeneic, Neutralizing, disease, Pfizer-BioNTech, BNT162b2 mRNA vaccination, BNT162b2 mRNA vaccine, GVHD, immunosuppressive, Safe, HSCT, Stem cell transplantation, confidence interval, Logistic regression analysis, Adverse, control group, 95% CI, second vaccination, domain, blood sample, multivariate, RBD IgG, healthy controls, fraction, recipient, controls, effective, Cell, event, geometric mean titre, HSCT recipients, chronic GVHD, analyzed, median, less, significantly higher, GMT, HSCT recipient, 【제목키워드】 COVID-19 vaccine, immunogenicity, BNT162b2 mRNA, Stem cell transplantation, recipient,